Tarsus Pharmaceuticals In...

NASDAQ: TARS · Real-Time Price · USD
53.52
-0.62 (-1.15%)
At close: Aug 15, 2025, 10:18 AM

Tarsus Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
182.95M 17.45M 25.82M 57.03M
Cost of Revenue
12.83M 1.59M 955K 2.08M
Gross Profit
170.13M 15.85M 24.86M 54.95M
Operating Income
-120.57M -143.16M -62.71M -12.16M
Interest Income
15.01M 10.34M 3.5M 36K
Pretax Income
-115.55M -135.89M -62.09M -13.77M
Net Income
-115.55M -135.89M -62.09M -13.83M
Selling & General & Admin
237.31M 108.7M 44.95M 25.4M
Research & Development
53.39M 50.31M 42.62M 41.71M
Other Expenses
n/a n/a 86K -73K
Operating Expenses
290.7M 159.01M 87.57M 67.11M
Interest Expense
7.85M 3.35M 2.2M n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
303.52M 160.6M 88.53M 69.18M
Income Tax Expense
n/a n/a -4K 55K
Shares Outstanding (Basic)
37.6M 29.38M 24.62M 20.55M
Shares Outstanding (Diluted)
37.6M 29.38M 24.62M 20.55M
EPS (Basic)
-3.07 -4.62 -2.52 -0.67
EPS (Diluted)
-3.07 -4.62 -2.52 -0.67
EBITDA
-106.48M -131.67M -59.11M -13.17M
EBIT
-108.11M -132.67M -59.9M -13.77M
Depreciation & Amortization
1.23M 877K 789K 606K